At CytoDyn we recognize the importance of the power of the human body to control disease. For that reason, as is the case in many other fields of medicine today we are looking to antibodies, the immune system’s own defense mechanism, for solutions to our most pressing human needs.

The field of HIV is rich with various stages of very potent daily treatment options. For this reason, CytoDyn as well as many other pharmaceutical companies are developing potentially long lasting solutions to ease the burden of treatment.

Read on to explore our approach. >>

CytoDyn is proud to announce the acquisition of a new antibody to its pipeline, PRO 140. PRO 140 has been under development by Progenics Pharmaceuticals and we are pleased to be able to continue the development of this potent monoclonal antibody therapeutic for HIV.

Acquiring PRO 140 provides CytoDyn with a late stage monoclonal antibody for the treatment and prevention of HIV infection. This addition compliments Cytolin, our existing early developmental stage antibody for HIV. We look forward to bringing our expertise in antibody development to bear on this additional project.

Read more about PRO 140, a phaseIIB monoclonal antibody targeted to HIV infection. >>

• CytoDyn Inc. Appoints Anthony D. Caracciolo as Chairman of the Board of Directors
• CytoDyn Announces Important Milestone Achieved to Initiate Phase IIb Studies
• BioWorld: MAb Purchase Fast Forwards CytoDyn’s HIV/AIDS Pipeline
• CytoDyn to Attend BIOCOM Global Life Sciences Partnering Conference
• CytoDyn Announces Collaboration with Dr. Bruce Torbett, The Scripps Research Institute, to Study PRO 140 in a Pre-exposure Prophylaxis (PrEP) Model of HIV Infection
• CytoDyn Announces Investor Update Conference Call on Friday, February 22
• About.com: Approaching HIV Treatment from a New Direction
• Daily Tribune: US Firm Offers New Treatment for HIV